U.S., Canada Pharma-Bio Capital Project Development Stays Strong Despite Pandemic, an Industrial Info Market Brief
U.S., Canada Pharma-Bio Capital Project Development Stays Strong Despite Pandemic, an Industrial Info Market Brief
Attachment: Pharma
As North America's manufacturing sector deals with COVID-19, pharma-bio capital development remains robust. This cohort is realizing five distinct lessons from the pandemic: 1) Plan ahead -- have a contingency plan in place for any future crisis; 2) Have a wide network of support-supply chains that are being widened, and material stockpiled; 3) Go local when possible --although sometimes more costly, firms are trending toward local suppliers; 4) Leverage AI, automation and robotics, while relying less on the human factor in order to prevent long work stoppages, and; 5) Obtain a scaling plan; the ability to scale up when needed.
Industrial Info is tracking more than 900 U.S. and Canadian pharma-bio capital projects that are in the planning or engineered phases in the U.S. with a total investment value of $40 billion.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021